Company intelligence / Profile preview
101 Therapeutics
Israel101therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
101 Therapeutics has developed a novel COVID-19 treatment that has shown exceptional efficacy against the virus and its variants. The treatment binds to immune cells called macrophages, signaling them to undergo apoptosis, which helps remove infected cells from the body and stops dangerous immune overreactions (cytokine storms). The company is currently in Phase 2 clinical trials as of April 2025[2][3].
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Small molecule drugsTargeted glucocorticoids
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Awz (Canadian-Israeli venture capital firm)
Beyond the preview
Go deeper on 101 Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 101 Therapeutics.